Sharemaestro Newsreel

Bausch Health earnings up next as analysts eye profit surge

Bausch Health Companies Inc. is set to report second-quarter earnings, with analysts anticipating a significant profit surge. The company is expected to post earnings of $1.01 per share on revenue of $2.67 billion, driven by improving operating leverage and strategic initiatives like international expansion. …

FDA closes Alvotech (NASDAQ: ALVO) Iceland plant inspection with VAI status

Alvotech (NASDAQ: ALVO) announced that the U.S. FDA has closed its May 2026 inspection of its Reykjavik, Iceland manufacturing facility with a Voluntary Action Indicated (VAI) classification. The company views this as a significant milestone, reflecting enhanced quality systems and manufacturing operations. Alvotech continues …

Anika Therapeutics Releases Q2 2026 Financial Results

Anika Therapeutics, Inc. reported a significant turnaround in Q2 2026, with adjusted earnings of $0.42 per share, exceeding expectations by 625.0%. The company's revenue increased by 16.0% to $32.6M, driven by strong growth in both its Commercial and OEM channels. This return to profitability …

Haleon PLC (LSE:HLN) Q2 2026 Earnings Report Preview: What to Look For

Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss

Researcher with pipette ©National Institutes of Health Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported mixed second-quarter results, with revenue exceeding Wall Street expectations while adjusted earnings fell short due to acquisition-related costs. Investors focused on the company's strong sales growth from its key branded medicines, …

Alvotech clears FDA inspection of Iceland manufacturing site, advancing biosimilar drug approvals.

Alvotech announced the successful closure of an FDA inspection at its manufacturing facility in Reykjavik, Iceland, which was classified as Voluntary Action Indicated (VAI). This clearance is a crucial step for Alvotech, allowing the company to advance its biosimilar drug pipeline. The company is …

Alvotech works toward FDA approval for three biosimilar applications

Alvotech announced that the FDA has closed its May 2026 inspection of the company's Reykjavik manufacturing facility with a Voluntary Action Indicated (VAI) classification, indicating concerns that the firm is asked to address voluntarily. This positive outcome reflects the company's efforts to strengthen quality …

Alvotech announces successful closure of FDA inspection of manufacturing facility

Alvotech announced the successful closure of an FDA inspection of its Reykjavik, Iceland manufacturing facility, with the FDA classifying the site as Voluntary Action Indicated (VAI). This is a significant milestone for Alvotech, demonstrating strengthened quality systems and manufacturing operations. The company is confident …

Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026

Liquidia Corporation announced it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss these results and provide a corporate update. Liquidia is a biopharmaceutical company focused …

Anika Therapeutics Q2 2026 slides: margins surge, guidance raised

Anika Therapeutics reported Q2 2026 results that significantly exceeded analyst expectations, with adjusted earnings of $0.42 per share and revenue of $32.6 million. The company's shares surged on the news, driven by a successful operational transformation leading to expanded gross margins of 65% and …

Zoetis (ZTS) Slid on Weak Response to Great Ideas

Platinum Asset Management, an investment management company, released its Q2 2026 investor letter for "Platinum International Brands Fund". A copy of the letter can be downloaded here. The fund returned over 4% in the quarter but lost 14% over the past year, primarily due …

Perrigo executives set for Aug. 12 webcast at 10:30 a.m.

Perrigo (NYSE: PRGO) announced that its Interim President and CEO, Albert Manzone, and CFO, Eduardo Bezerra, will present at the Canaccord 46th Annual Growth Conference on Wednesday, August 12, at 10:30 AM EDT. The presentation will be webcast live on the company's investor relations …

Stephen Bloch Sells 75,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Director Stephen Bloch recently sold 75,000 shares of Liquidia (NASDAQ:LQDA) stock for approximately $6.0 million, reducing his ownership by 9.66%. The sale occurred when Liquidia shares were trading near their 12-month high, following a strong quarterly earnings report that exceeded analyst expectations. Liquidia currently …

Liquidia schedules 8:30 a.m. webcast for Aug. 12 results

Liquidia Corporation (Nasdaq: LQDA) announced it will report its second-quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update, with rebroadcast available for one year. …

Cardiol Therapeutics Stock Climbs 3.66%: Clinical Development Progress and Biotechnology Innovation Strengthen Investor Confidence

Cardiol Therapeutics (TSX: CRDL) saw its stock climb 3.66% during the latest trading session, driven by renewed investor interest in the biotechnology sector. The company, which focuses on developing therapies for cardiovascular diseases, benefited from optimism surrounding innovative clinical development and increasing healthcare investment. …

Akebia Therapeutics, Inc. Revenue Breakdown – BX:AX9

Akebia Therapeutics, Inc. (BX:AX9) generated 187.25 million CHF last year, with its Innovative Therapeutics segment being the top performer. All of this revenue came from the United States market, indicating a focused geographic revenue stream. This represents an increase from 145.48 million CHF the …

Teva shares rise 3% on Q2 top-line beat as key brands deliver strong performance

Teva Pharmaceutical Industries Ltd. reported mixed Q2 results, with revenue exceeding expectations at $4.14 billion due to strong performance from key innovative brands like AUSTEDO, AJOVY, and UZEDY. Despite an adjusted EPS miss ($0.02 vs. $0.62 consensus) largely due to acquisition expenses, shares rose …

Teva Pharmaceutical Industries Releases Q2 2026 Financial Results

Teva Pharmaceutical Industries Limited reported a significant earnings miss for Q2 2026, with non-GAAP diluted earnings of $0.02 per share against a $0.32 estimate, missing by 93.8%. The company's revenue for the quarter was $4.14B, a 1.0% decrease year-over-year, largely due to a 5.0% …

Teva stock gains after Q2 revenue beat (TEVA:NYSE)

Teva Pharmaceutical (TEVA) saw its stock increase by approximately 3% in premarket trading after reporting better-than-expected Q2 2026 revenues, despite a decline in generic product sales. The company also announced plans for a direct NYSE listing, aiming to expand its shareholder base and reduce …

Harrow Inc (HROW) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Harrow Inc (HROW), noting its current valuation score of 9.51, which ranks 17th out of 155 companies in the Pharmaceuticals industry. It highlights the company's P/E ratio is -101.17, significantly below its recent high and above its …

TSX Penny Stocks To Watch In July 2026

This article identifies three TSX penny stocks—Cronos Group (TSX:CRON), Cannara Biotech (TSX:LOVE), and BioRem (TSXV:BRM)—that present intriguing opportunities for investors in July 2026, considering the Canadian market's response to rising oil prices and interest rates. Each company is highlighted for its balance sheet strength …

Akebia plans Aug. 5 webcast after markets close to discuss results

Akebia Therapeutics (Nasdaq: AKBA) will release its second-quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. The company will host a conference call at 4:30 p.m. EDT on the same day to discuss the results and recent business highlights, accessible …

Earnings Flash (TEVA) Teva Pharmaceutical Industries Ltd. Reports Q2 Revenue $4.14B, vs. FactSet Est of $4.02B

Teva Pharmaceutical Industries Ltd. (TEVA) announced its Q2 revenue at $4.14 billion, surpassing FactSet estimates of $4.02 billion. The company also updated its earnings and revenue guidance for the full year 2026, despite reporting lower Q2 adjusted earnings and revenue. Teva's CEO also indicated …

Anika Therapeutics Q2 2026: Revenue $32.6M, Gross Margin 65%, Net Income $3.3M

Anika Therapeutics reported strong Q2 2026 results, with revenue reaching $32.6 million, a 16% year-over-year increase, and a gross margin of 65%. The company achieved a net income of $3.3 million and adjusted diluted EPS of $0.42. Management raised its full-year 2026 revenue and …

Journey Medical Corp (DERM) Institutional Confidence

Journey Medical Corp (DERM) has an institutional shareholding score of 5.00, ranking 72nd out of 156 in the Pharmaceuticals industry. The institutional shareholding proportion has increased by 93.34% quarter-over-quarter to 56.62%. The largest institutional shareholder is Bill Nygren from OAKMX, holding 1.67 million shares, …

Zhengye Biotechnology Holding Ltd (ZYBT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Zhengye Biotechnology Holding Ltd (ZYBT), detailing its support, resistance levels, and performance based on various technical indicators and moving averages. According to the analysis, the overall signal for ZYBT is Neutral, with specific indicators showing mixed signals …

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET

Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these …

Eton seeks FDA expansion of hydrocortisone liquid for children under 5

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the label of its KHINDIVI oral solution to include pediatric adrenal insufficiency patients under five years old. A new formulation of KHINDIVI demonstrated bioequivalence to an FDA-approved hydrocortisone granule formulation, potentially …

Anika: Q2 Earnings Snapshot

This article provides a second-quarter earnings snapshot for Anika. It contains no financial details or further information about the company's performance. The article is exceptionally brief, offering only a title without substantive content.

Anika Therapeutics Q2 revenue rises, lifts 2026 outlook

Anika Therapeutics reported a rise in its second-quarter revenue, leading the company to subsequently lift its financial outlook for 2026. This positive performance and improved forecast were highlighted in a Reuters news brief accessible via TradingView.

Evotec SE Sponsored ADR Revenue Breakdown – FWB:EVTA

Evotec SE Sponsored ADR (FWB:EVTA) generated a total revenue of 785.01 million EUR last year. The primary segment contributing to this revenue was Discovery & Preclinical Development, which brought in 508.24 million EUR. The United States was the largest geographical contributor, accounting for 414.63 …

BioXcel Therapeutics Inc (BTAI) Institutional Confidence

This article from TradingKey provides an overview of BioXcel Therapeutics Inc (BTAI)'s institutional confidence, based on an updated score of 3.00 as of July 28, 2026. It details the shares held by various institutional investors and Star Investors, along with the percentage change in …

BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioXcel Therapeutics Inc (BTAI), highlighting its current valuation score of 8.84 within the Pharmaceuticals industry. It also details the company's P/E ratio, noting that other relevant financial data such as P/B, P/S, and P/CF have not yet …

Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch

Viatris Inc. announced that the U.S. FDA has approved Gwyn Lo™, a new once-weekly combined hormonal contraceptive patch. This low-dose estrogen patch is indicated for women of childbearing potential with a BMI below 30 kg/m² and demonstrated efficacy and a well-characterized safety profile in …

Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI (hydrocortisone) oral solution to include younger pediatric patients. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, and the company anticipates potential approval in the first half of …

Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Collegium Pharmaceutical Inc (COLL), detailing its volatility, financial risk, and investment risk. The company has a risk assessment score of 7.30, ranking 37 out of 155 in the Pharmaceuticals industry, with a beta of 0.75 indicating underperformance …